Project Details
Description
We propose superiority pragmatic randomized clinical trials in two clinical settings. The unifying hypothesis is that, as part of multi-modality curative treatment for locally-advanced breast and lung cancer, proton therapy reduces fatal and non-fatal major cardiovascular events compared to photon-based therapy. Fatal and non-fatal major cardiovascular events include cardiovascular heart disease death, myocardial infarction, cardiovascular revascularization procedures, and hospitalization for unstable angina. A complementary hypothesis is that proton therapy yields no worse breast and lung local-regional cancer recurrence than photon-based therapy. Each trial is designed with patient-centric short-term endpoints (both clinician and patient reported) that can be examined within the PCORI contract duration. We will evaluate meaningful long-term morbidity and mortality endpoints with future funding from NCI, PCORI or other agencies.
Setting 1. Post-mastectomy and locally-advanced breast cancer. H1. The proton beam therapy group will experience no worse local-regional cancer recurrence and reductions in long-term fatal and non-fatal major cardiovascular events.
Setting 2. Post-operative non-small cell lung cancer. The proton beam therapy group will experience no worse local-regional cancer recurrence and reductions in long-term fatal and non-fatal major cardiovascular events.
Status | Finished |
---|---|
Effective start/end date | 11/1/15 → 10/31/22 |
Funding
- University of Pennsylvania (567804 // PCS-1403-12804 007)
- Patient-Centered Outcomes Research Institute (567804 // PCS-1403-12804 007)
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.